Cargando…

How to select colorectal cancer patients for personalized therapy

Detalles Bibliográficos
Autores principales:	Pfeiffer, Per, Qvortrup, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442646/ https://www.ncbi.nlm.nih.gov/pubmed/30797710 http://dx.doi.org/10.1016/j.ebiom.2019.02.022

Ejemplares similares

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
por: Winther, Stine Braendegaard, et al.
Publicado: (2016)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol
por: Justesen, Tobias Freyberg, et al.
Publicado: (2023)

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Commentary: how person-centred is pharmaceutical care?
por: Gyllensten, Hanna, et al.
Publicado: (2021)

Congenital hypopituitarism: how to select the patients for genetic analyses
por: Crisafulli, Giuseppe, et al.
Publicado: (2018)

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone
por: Cavalli-Björkman, N, et al.
Publicado: (2012)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

Cervical cancer genomics: an initial step towards personalized approach to therapy
por: Srinivasan, Radhika
Publicado: (2019)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

How targets select activation or repression in response to Wnt
por: Murgan, Sabrina, et al.
Publicado: (2015)

“Hi Mr belly” - A personal perspective on the obesity crisis and how to tackle it
por: Pakdemirli, Emre
Publicado: (2019)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al
por: Deming, Dustin A.
Publicado: (2016)

Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer
por: El Sissy, Carine, et al.
Publicado: (2021)

Dysbiotic drift and biopsychosocial medicine: how the microbiome links personal, public and planetary health
por: Prescott, Susan L., et al.
Publicado: (2018)

Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer
por: Hafezi, Morteza, et al.
Publicado: (2021)

Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node‐positive breast cancer: How can we select patients?
por: van Zeeland, Marianne, et al.
Publicado: (2020)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Elderly patients for cancer surgeries: How much to investigate!
por: Garg, Rakesh
Publicado: (2018)

c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?
por: Schmitt, Fernando C, et al.
Publicado: (2003)

Commentary: The physician as person framework: How human nature impacts empathy, depression, burnout, and the practice of medicine
por: Dagnone, J Damon
Publicado: (2017)

Patient, prisoner or person?
por: Small, Dan
Publicado: (2006)

How the vertebrates were made: selective pruning of a double-duplicated genome
por: Manning, Gerard, et al.
Publicado: (2010)

Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?
por: Golan, Yoav
Publicado: (2009)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

How important is gametocyte clearance after malaria therapy?
por: Karunajeewa, Harin A., et al.
Publicado: (2016)

The quest for personalized B-cell depletion therapy in rheumatic disease
por: Nistala, Kiran, et al.
Publicado: (2014)

Network-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy
por: Cao, Peng, et al.
Publicado: (2023)

Biological and Clinical Relevance of H19 in Colorectal Cancer Patients
por: Schwarzenbach, Heidi
Publicado: (2016)

PP2A Level in Colorectal Cancer Cells Predicts the Response of p38 Targeted Therapy
por: Shang, Chaowei, et al.
Publicado: (2015)

The Challenge of Metastatic Colorectal Cancer
por: Cidón, Esther Uña
Publicado: (2010)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Goal directed therapy: how long can we wait?
por: Gordon, Anthony C, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_mulmr0o002hqc2aepk6tkgqelu